Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Prognostic factors and seizure outcome in posterior reversible encephalopathy syndrome (PRES) in children with hematological malignancies and bone marrow failure: A retrospective monocentric study

P. Danhofer, M. Tomečková, D. Černá, D. Zapletalová, O. Horák, Š. Aulická, L. Juříková, J. Domanský, P. Kovalčíková, T. Pavlík, J. Štěrba, H. Ošlejšková,

. 2019 ; 72 (-) : 1-10. [pub] 20190815

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023566

PURPOSE: The aim of this study was to evaluate seizure outcome in children with hematological malignancies and PRES and to identify prognostic factors that could help manage the syndrome. METHOD: We retrospectively reviewed the report data of 21 patients diagnosed with hematological malignancy or aplastic anemia and PRES between 2008 and 2018. Basic demographic data, oncology treatment, presymptomatic hypertension before PRES manifestation, neurological status, seizure type, and EEG and MRI findings at PRES onset and at the one-year follow-up visit were studied. Patients who developed remote symptomatic seizures or epilepsy were identified. RESULTS: We included 21 children (11 females and 10 males) in the study. Sixteen patients (76.2%) were diagnosed with ALL and the rest individually with AML, CML, T-lymphoma, Burkitt lymphoma, and severe aplastic anemia. Presymptomatic hypertension (PSH) was evaluated in 19 patients and was present in 18 (94.7%). The duration was 9 h and more in 16 patients (88.8%); the severity was grade II in 12 patients (66.7%). Seizures as the initial symptom of PRES were present in 17 patients (80.9%). Four patients (19.0%) were assessed with remote symptomatic seizures. Two of them (9.5%) had ongoing seizures at the one-year follow-up visit and were diagnosed with epilepsy. The presence of gliosis on follow-up MRI indicated worse outcome with development of epilepsy (without statistical significance). CONCLUSIONS: PRES syndrome has an overall good prognosis and the evolution to epilepsy is rare. The severity and duration of PSH or seizure severity and EEG findings at PRES onsetwere not associated with worse neurological outcomes in this study.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023566
003      
CZ-PrNML
005      
20240125144102.0
007      
ta
008      
201125s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.seizure.2019.08.007 $2 doi
035    __
$a (PubMed)31521834
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Danhofer, Pavlína $u Epilepsy Center Brno, Department of Child Neurology, University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic. Electronic address: pavlina.cahova@seznam.cz.
245    10
$a Prognostic factors and seizure outcome in posterior reversible encephalopathy syndrome (PRES) in children with hematological malignancies and bone marrow failure: A retrospective monocentric study / $c P. Danhofer, M. Tomečková, D. Černá, D. Zapletalová, O. Horák, Š. Aulická, L. Juříková, J. Domanský, P. Kovalčíková, T. Pavlík, J. Štěrba, H. Ošlejšková,
520    9_
$a PURPOSE: The aim of this study was to evaluate seizure outcome in children with hematological malignancies and PRES and to identify prognostic factors that could help manage the syndrome. METHOD: We retrospectively reviewed the report data of 21 patients diagnosed with hematological malignancy or aplastic anemia and PRES between 2008 and 2018. Basic demographic data, oncology treatment, presymptomatic hypertension before PRES manifestation, neurological status, seizure type, and EEG and MRI findings at PRES onset and at the one-year follow-up visit were studied. Patients who developed remote symptomatic seizures or epilepsy were identified. RESULTS: We included 21 children (11 females and 10 males) in the study. Sixteen patients (76.2%) were diagnosed with ALL and the rest individually with AML, CML, T-lymphoma, Burkitt lymphoma, and severe aplastic anemia. Presymptomatic hypertension (PSH) was evaluated in 19 patients and was present in 18 (94.7%). The duration was 9 h and more in 16 patients (88.8%); the severity was grade II in 12 patients (66.7%). Seizures as the initial symptom of PRES were present in 17 patients (80.9%). Four patients (19.0%) were assessed with remote symptomatic seizures. Two of them (9.5%) had ongoing seizures at the one-year follow-up visit and were diagnosed with epilepsy. The presence of gliosis on follow-up MRI indicated worse outcome with development of epilepsy (without statistical significance). CONCLUSIONS: PRES syndrome has an overall good prognosis and the evolution to epilepsy is rare. The severity and duration of PSH or seizure severity and EEG findings at PRES onsetwere not associated with worse neurological outcomes in this study.
650    _2
$a mladiství $7 D000293
650    _2
$a syndromy selhání kostní dřeně $x komplikace $x diagnostické zobrazování $x patofyziologie $7 D000080983
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a kohortové studie $7 D015331
650    _2
$a elektroencefalografie $x metody $7 D004569
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a hematologické nádory $x komplikace $x diagnostické zobrazování $x patofyziologie $7 D019337
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a syndrom zadní leukoencefalopatie $x komplikace $x diagnostické zobrazování $x patofyziologie $7 D054038
650    _2
$a prognóza $7 D011379
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a záchvaty $x komplikace $x diagnostické zobrazování $x patofyziologie $7 D012640
655    _2
$a časopisecké články $7 D016428
700    1_
$a Tomečková, Michaela $u Epilepsy Center Brno, Department of Child Neurology, University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Černá, Dáša $u Pediatric Oncology Department, University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Zapletalová, Danica $u Pediatric Oncology Department, University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Horák, Ondřej $u Epilepsy Center Brno, Department of Child Neurology, University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Aulická, Štefánia $u Epilepsy Center Brno, Department of Child Neurology, University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Juříková, Lenka $u Epilepsy Center Brno, Department of Child Neurology, University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Domanský, Jiří $u Pediatric Oncology Department, University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic. $7 xx0313150
700    1_
$a Kovalčíková, Petra $u Institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Pavlík, Tomáš $u Institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Štěrba, Jaroslav $u Pediatric Oncology Department, University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
700    1_
$a Ošlejšková, Hana $u Epilepsy Center Brno, Department of Child Neurology, University Hospital and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
773    0_
$w MED00004310 $t Seizure $x 1532-2688 $g Roč. 72, č. - (2019), s. 1-10
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31521834 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20240125144057 $b ABA008
999    __
$a ok $b bmc $g 1595885 $s 1114242
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 72 $c - $d 1-10 $e 20190815 $i 1532-2688 $m Seizure $n Seizure $x MED00004310
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace